Dr. Joel Schlessinger, MD

Dr. Schlessinger practices at Schlessinger MD in Omaha, Nebraska.

Dr. Schlessinger's NPI, 1720085582, was assigned on July 7, 2005. Dr. Schlessinger graduated from Baylor College of Medicine in 1985. Dr. Schlessinger holds Nebraska license 18783.

Dr. Schlessinger's primary practice is Schlessinger MD, at 2802 Oak View Dr, Omaha, NE 68144. The practice phone is (402) 334-7546.

Dr. Schlessinger's primary practice is Schlessinger MD in Omaha, Nebraska. Dr. Schlessinger is also affiliated with Nebraska Medical Center. The medical group on file is Schlessinger MD. Dmand AI also links Dr. Schlessinger to 1 more group practice or clinic, named with a free account. Dr. Schlessinger's employer is on file too: a surgery center (asc).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schlessinger practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Schlessinger's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dmand AI has Dr. Schlessinger's licenses on file in 2 states: Nebraska and Iowa.

CMS data shows 3,681 Medicare services from Dr. Schlessinger across 16 procedure codes in 2024, for 432 Medicare patients. Medicare paid $152,838 for them. Every service was in an office.

CMS counts 432 Medicare patients who saw Dr. Schlessinger in 2024. The largest group is 65 to 74, with 226 patients. 70% of them have high cholesterol, and 62% have high blood pressure. Their average risk score is 0.84, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Schlessinger's median patient age at 48, with 59% women.

In 2024, Dr. Schlessinger wrote 1,733 Medicare Part D claims for 539 patients. 96% of them were for generic drugs. CMS names the drug for 1,579 of them, across 20 drugs with 11 or more claims each, at $97,978 in total drug cost. In 2023, CMS named 1,143 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Schlessinger for performance year 2024, reported as part of a group. Dr. Schlessinger accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 542 procedures of skin biopsy by Dr. Schlessinger, more than 96% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal of skin cancer: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 45 papers to Dr. Schlessinger, published from 2011 to 2025. 2013 was the busiest year, with 2. The most frequent topics are Double-Blind Method, Skin Aging and Patient Satisfaction. Dr. Schlessinger has published most often in J Drugs Dermatol. Dr. Schlessinger's most frequent co-authors are Joely A. Kaufman-Janette, MD, Joel Lee Cohen, MD and Joel Cohen, MD.

Dmand AI links Dr. Schlessinger to 9 clinical trials, 3 of them phase 2 studies. Conditions studied include Eczema, Dermatitis, Atopic and Cellulite. Eli Lilly and Company sponsors the most, 4. Open Payments lists research payments to Dr. Schlessinger that name 7 trials.

CMS Open Payments shows 387 general payments to Dr. Schlessinger from 22 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 56% of the total. Allergan Inc. paid the most, $83,664. It also lists 34 research payments totaling $227,298 from 2016 to 2025, naming 7 clinical trials.

Dr. Schlessinger graduated from Baylor College of Medicine in 1985.